# Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension

Study · id `cardio:ct-nct04952051` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04952051](<https://clinicaltrials.gov/study/NCT04952051>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04952051

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.

## Technical summary

Registry record NCT04952051. Randomized; no masking; primary purpose treatment. Start 2014-07-01 (actual); primary completion 2019-07-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1000 participants (enrolled count; ClinicalTrials.gov record NCT04952051, source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)
- Started: 2014-07-01 (actual) (ClinicalTrials.gov record NCT04952051, source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)
- Primary completion: 2019-07-31 (actual) (ClinicalTrials.gov record NCT04952051, source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)
- Completion: 2020-07-01 (actual) (ClinicalTrials.gov record NCT04952051, source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04952051, source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04952051-2021-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension
- Condition: Hypertension
- Intervention (Drug): Enalapril Folic Acid Tablets Combined With amlodipine
- Intervention (Drug): Enalapril Folic Acid Tablets Combined With hydrochlorothiazide
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER
- Collaborator: National Clinical Research Center, Southern Medical University
- Collaborator class: UNKNOWN
- Collaborator: Ningbo Yinzhou Community Health Service Center
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 7f94a7de706d9dfe0f376e931c768f42ae4a7f12a521f7e88d1673026ebd3b0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
